



This is a repository copy of *Increased recombinant adeno-associated virus production by HEK293 cells using small molecule chemical additives.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/195018/>

Version: Published Version

Article:

Scarrott, J.M. orcid.org/0000-0002-6046-7687, Johari, Y.B. orcid.org/0000-0001-9933-5764, Pohle, T.H. et al. (3 more authors) (2023) Increased recombinant adeno-associated virus production by HEK293 cells using small molecule chemical additives. *Biotechnology Journal*, 18 (3). 2200450. ISSN 1860-6768

<https://doi.org/10.1002/biot.202200450>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

ON-DEMAND Webinars

L'Oréal: Design experiments to be robust to input variation

Victor Guiller
Scientific Expertise
Engineer, L'Oréal



Video

RESEARCH ARTICLE

Increased recombinant adeno-associated virus production by HEK293 cells using small molecule chemical additives

Joseph M. Scarrott¹  | Yusuf B. Johari¹  | Thilo H. Pohle¹ | Ping Liu² | Ayda Mayer² | David C. James¹

¹Department of Chemical and Biological Engineering, University of Sheffield, Sheffield, UK

²Cell Line Development, REGENXBIO Inc., Rockville, Maryland, USA

Correspondence

David C. James, Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield S1 3JD, UK.
Email: d.c.james@sheffield.ac.uk

Present address

Yusuf B. Johari, Lonza Biologics, Cambridge, UK

Abstract

Recombinant adeno-associated virus (rAAV) has established itself as a highly efficacious gene delivery vector with a well characterised safety profile allowing broad clinical application. Recent successes in rAAV-mediated gene therapy clinical trials will continue to drive demand for improved rAAV production processes to reduce costs. Here, we demonstrate that small molecule bioactive chemical additives can significantly increase recombinant AAV vector production by human embryonic kidney (HEK) cells up to three-fold. Nocodazole (an anti-mitotic agent) and M344 (a selective histone deacetylase inhibitor) were identified as positive regulators of rAAV8 genome titre in a microplate screening assay. Addition of nocodazole to triple-transfected HEK293 suspension cells producing rAAV arrested cells in G2/M phase, increased average cell volume and reduced viable cell density relative to untreated rAAV producing cells at harvest. Final crude genome vector titre from nocodazole treated cultures was >2-fold higher compared to non-treated cultures. Further investigation showed nocodazole addition to cultures to be time critical. Genome titre improvement was found to be scalable and serotype independent across two distinct rAAV serotypes, rAAV8 and rAAV9. Furthermore, a combination of M344 and nocodazole produced a positive additive effect on rAAV8 genome titre, resulting in a three-fold increase in genome titre compared to untreated cells.

KEYWORDS

bioprocess engineering, CHO cells, gene expression, mammalian cells, protein expression, recombinant proteins, synthetic biology, systems biology

Abbreviations: CHO, Chinese hamster ovary; ddPCR, digital droplet PCR; eGFP, enhanced green fluorescent protein; GMP, Good Manufacturing Practice; HEK, human embryonic kidney; HPT, hours post-transfection; LiCl, lithium chloride; NaBu, sodium butyrate; PEI, polyethyleneimine; PI, propidium iodide; rAAV, recombinant adeno-associated virus; TMAO, trimethylamine N-oxide; TUDCA, tauroursodeoxycholic acid; VPA, valproic acid.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. *Biotechnology Journal* published by Wiley-VCH GmbH

1 | INTRODUCTION

Recent regulatory approvals for recombinant adeno-associated virus (rAAV) mediated gene therapy products (Luxturna in 2017 and Zolgensma in 2019) – together with a significant increase in the number of rAAV gene therapies in clinical trials^[1,2] – has highlighted the need for improved production process technology with respect to titre, product quality and cost. Indeed, the high cost of manufacturing rAAV gene therapies to support the typically high therapeutic dosages used (e.g., 6×10^{13} – 2×10^{14} vector genomes/kg^[3]) has limited the economic viability of AAV gene therapies despite evidence of promising clinical efficacy. Therefore, there is an urgent need for robust, intensified process technology to support production of Good Manufacturing Practice (GMP) quality material. As nearly all current rAAV production processes rely on co-transfection of three plasmids encoding the necessary AAV and helper genes into HEK293 cell hosts for transient production of rAAV within 3–5 days,^[4] efficient use of plasmid DNA (itself produced using a costly GMP-approved process) is also of paramount importance.

rAAV is a complex macromolecular product requiring a diverse network of cellular processes and molecular interactions to enable coordinated cellular synthesis – involving host-cell proteins, transiently expressed viral helper, capsid and replicase genes, as well as the single stranded therapeutic viral DNA payload itself.^[5–7] Small molecule enhancers of recombinant protein production have demonstrated efficacy in a wide variety of mammalian cell lines^[3,8,9] and the addition of chemicals as diverse as sodium chloride, sodium butyrate (NaBu) and soy peptones have been shown in previous studies to improve rAAV production yields.^[9–11] Targeting of discrete pathways involved in the replication, packaging and trafficking of viral particles by bioactive small molecule cell culture additives offers a simple and cost-effective way of increasing viral titre and reducing overall production costs.

Here, we show that microplate plate-based screening of chemical additives can be used to rapidly identify positive effectors of rAAV synthesis in human embryonic kidney (HEK) cells and that significant improvements in viral genome titre can be obtained by subsequent optimisation of dosing regimen. Furthermore, we also demonstrate that a combination of two functionally distinct small molecule enhancers may act additively, resulting in a three-fold increase in viral vector genome titre and thus a substantial improvement in the efficiency of plasmid DNA usage.

2 | EXPERIMENTAL SECTION

2.1 | Cell culture

Proprietary suspension adapted HEK293 cells were provided by REGENXBIO (Rockville, MD). Cells were cultured in a serum free medium supplemented with L-glutamine (Thermo Scientific, Waltham, MA). Cells were maintained in an orbital shaking incubator (Infors, Bottmingen, Switzerland) at 30 ml culture volumes in 125 ml Erlen-

meyer flasks (Corning) at 37°C, 5% CO₂ and 85% humidity, with agitation at 140 rpm. Smaller scale cultures were grown in shallow-well 24-well plates (0.7 ml culture volume/well, 240 rpm shaking) (Corning, Acton, MA) using the Deutz system.^[12] Routine cell density and cell viability measurements were performed on a ViCell automated cell counter (Beckman-Coulter, Brea, CA). Measurements of density and viability and determination of mean cell volume during rAAV production runs were performed using the Norma HT system (Iprasense) utilising 3 μ l total cell culture and 20 μ m slide chambers. Mean cell volume (*V*) was calculated as $V = \frac{4}{3} \pi r^3$ where *r* = measured cell diameter/2.

2.2 | rAAV vector production in suspension adapted HEK293 cells

An HEK293-derived cell line adapted to suspension in Dynamis media, SKMB (REGENXBIO Inc.), was subjected to a triple-transfection protocol as previously described,^[13] with the following modifications: (1) cis plasmid containing an enhanced green fluorescent protein (eGFP) expression cassette flanked by AAV2 inverted terminal repeats (ITRs); (2) trans plasmids pAAV2/8 and pAAV2/9 containing the AAV2 rep gene and capsid protein genes from AAV8 and 9, respectively and (3) adenovirus helper plasmid pAdDeltaF6 were transfected using polyethyleneimine (PEI) (Polyplus Transfection, Illkirch, France) according to the manufacturer's instructions. Plasmids and PEI were diluted in media and incubated at room temperature, then added to cells. For analysis, 450 μ l of total cell culture was added to 50 μ l 10x cell lysis buffer containing 1x cComplete, EDTA-free Protease Inhibitor Cocktail (Roche) and incubated for 1 h at 37°C with gentle agitation. Samples were briefly centrifuged at 12,000 RPM to remove cell debris and the resulting supernatant used to determine viral genome and capsid titre.

2.3 | Measurement of rAAV genome titre

Genome titre was quantified by digital droplet PCR (ddPCR). Aliquots of post-lysis supernatant (5 μ l) from total cell culture were treated with DNase I (Roche, Basel, Switzerland) to remove residual plasmid DNA. DNase I-treated samples were diluted 1000- or 10,000-fold in PCR dilution buffer (GeneAmp PCR Buffer I [Thermo Scientific], 0.02% UltraPure Salmon Sperm DNA Solution [Invitrogen, Waltham, MA], 0.1% Pluronic F-68 non-ionic surfactant). Droplet formation and subsequent post-PCR droplet analysis were performed using the QX200 system (Bio-Rad, Hercules, CA), with absolute quantification of AAV genome copies/ μ l determined using the Qantasoft analysis software (Bio-Rad). Genome detection was achieved using primers and an FAM-labelled probe targeting the PolyA sequence of the pAAV-CAG-GFP plasmid. Capsid titre quantification was performed using the AAV8 titration ELISA (Progen, Heidelberg, Germany) from total cell lysis supernatant diluted in 1x ASSB assay buffer (Progen).

2.4 | Chemical additive screening in microplates

Chemical additives for screening were diluted in either sterile water or dimethyl sulphoxide (DMSO, 100% v/v) where appropriate. Low, medium and high concentrations for each chemical were based on available literature describing their observed effects on recombinant protein expression in vitro (listed in Table S1). Cells were initially grown to a density of 4×10^6 viable cells/ml in Erlenmeyer flasks and mid-exponential phase cells were transfected with AAV-encoding plasmids prior to transferring to 24-shallow-well microplates (Corning) at 2.8×10^6 cells per well, 20 min post-transfection. Chemical additives were added to cells 24 hours post-transfection (HPT). Cell cultures were harvested at 72 HPT for viral genome titre analysis by ddPCR.

2.5 | HEK cell DNA content analysis by flow cytometry

Cells (1×10^6) were harvested 72 HPT and fixed in 70% v/v EtOH at 4°C for 30 min, with gentle vortexing to prevent clumping. EtOH was removed and the cells washed twice in 1x PBS. Fixed cells were treated with 100 μ l RNase A (100 μ g/ml in PBS; Qiagen) for 5 min at RT and the DNA stained with the subsequent addition of 400 μ l propidium iodide (PI) (50 μ g/ml in PBS; Thermo Scientific) at room temperature for a minimum of 30 min. PI-stained cells were analysed by flow cytometry using an LSRII instrument (BD Biosciences). Gated single cell populations were detected based on PI signal and the resulting histograms analysed using FlowJo software to determine the relative distribution of cells within the cell cycle (G1/S/G2-M) phases.

2.6 | Immunocytochemistry

rAAV producing cells were harvested 24 h after nocodazole addition. 1×10^6 cells were spun down at 250 g for 5 min, culture media was removed and cells resuspended in 1 ml PBS. Resuspended cells were incubated with no agitation for 30 min at RT and allowed to adhere by gravity sedimentation to lysine-coated glass coverslips in 24-well plates. After 30 min, PBS and unadhered cells were removed by gentle aspiration. Adhered cells were fixed by 10 min incubation at RT with 0.5 ml 4% v/v paraformaldehyde in PBS. Fixed cells were washed with PBS before permeabilisation with 0.5 ml 0.5% v/v Triton-X100 for 10 min. Permeabilised cells were blocked by 10% normal goat serum (Life Technologies, Carlsbad, CA; #016201) in PBS for 30 min. Cells were then incubated with anti-Fibrillar antibody (Abcam, Cambridge, UK; ab5821, 0.1 μ g/ml in blocking buffer) for 1 h at RT before incubation with goat anti-Rabbit Alexa-594 conjugated secondary antibody (Abcam; ab150080, 1:1000 dilution in blocking buffer) for 45 min at room temperature. Coverslips were transferred to a glass slide and mounted with Fluoroshield mounting media containing DAPI (Sigma-Aldrich; F6507) for visualisation of nuclei. Slides were imaged using a Nikon Eclipse Ti fluorescent microscope and images adjusted for brightness and contrast using ImageJ software.

2.7 | Request for materials

All requests for materials used in this article should be directed to the primary author at: j.scarrott@sheffield.ac.uk.

3 | RESULTS

3.1 | Initial screening of chemical additives to increase AAV genome titre

To identify novel small molecule enhancers of rAAV production, a panel of 15 small molecule culture additives was chosen based on either their reported propensity to increase recombinant protein expression in mammalian cell systems or their reported positive effects on rAAV transduction efficiency. Due to the diverse mechanisms involved in AAV vector production, the panel featured chemicals that exert their influence on recombinant protein expression via a broad range of functional mechanisms. Specifically, we tested chemicals reported to be “chemical chaperones” (tauroursodeoxycholic acid [TUDCA], trimethylamine N-oxide [TMAO], betaine),^[14–16] cell cycle modulators (nocodazole, BI-2536),^[17,18] caspase inhibitors (z-VAD-fmk),^[19] histone deacetylase inhibitors (NaBu, valproic acid [VPA], M344, apicidin),^[8,20–22] insulin-mimetics (lithium chloride [LiCl] and zinc sulphate)^[23] and proteasome inhibitors (ONX0912, MLN9708, MG132).^[24–26]

To enable multi-parallel screening of small molecule additives, we employed pre-optimised small-scale cultures (700 μ l culture volume) in 24-well microplates that exhibited a similar rAAV production profile to shake flask cultures (data not shown). Triple transfection was performed using PEI in a serum-free medium, and chemical additives were introduced to rAAV8-producing suspension HEK293 cells at 24 HPT. Each additive was used at three different concentrations (low, medium and high – values based on previous literature, see Table S1). Total cell culture was harvested at 72 HPT, cells were chemically lysed and the rAAV8 genome titre in the crude supernatant was measured by ddPCR. Crude genome titre in cells containing chemical additives was compared to that of untreated rAAV8 producing cells to determine changes to titre mediated by the small molecules. Several chemicals displayed a clear concentration-dependent impact on genome titre, both positively (z-VAD-fmk) and negatively (LiCl, ONX0912) (Figure 1A). Several compounds with similar mechanistic properties showed a marked reduction in rAAV titre at the tested concentrations – most notably inhibitors of proteasomal function (ONX0912, MLN9708, MG132) and the reported chemical chaperones (TUDCA, TMAO, betaine). Notably, the screening showed that high relative dose nocodazole (4 μ M) added to culture 24 HPT resulted in a 1.34-fold increase in rAAV8 titre compared to untreated control cells ($p = 0.62$, $n = 2$), while M344 appeared to be effective at low dose (2.5 μ M) with a 1.36-fold increase in rAAV8 titre ($p = 0.64$, $n = 2$). Of note, nocodazole treatment increased mean cell volume at all three concentrations, an attribute that appears to correlate positively with measured genome titre ($r^2 = 0.79$, $p < 0.0001$) (Figure 1B) and has been shown in previous reports to be a major




FIGURE 1 Initial screen of small molecule culture additives identifies nocodazole, M344 and z-VAD-fmk as novel putative enhancers of rAAV genome titre. Cells were analysed 72 HPT for rAAV8 genome titre, shown here as the fold change relative to rAAV8 producing cells containing no small molecule enhancers (Ctrl). Nocodazole, M344 and z-VAD-fmk are highlighted (dashed boxes) (A). Mean cell volume versus genome titre fold change is shown in (B), dashed lines indicate control values. R^2 and p -value calculated from Pearson correlation coefficient of mean cell volume versus genome titre. Data shown in (A) are mean \pm SEM for two independent experiments carried out in technical duplicate, with the exception of TUDCA, TMAO, betaine and LiCl which are mean only data from one independent experiment carried out in technical duplicate (data from these experiments is omitted in (B)). HPT, hours post-transfection; LiCl, lithium chloride; NaBu, sodium butyrate; rAAV, recombinant adeno-associated virus; SEM, standard error of mean; TMAO, trimethylamine *N*-oxide; TUDCA, tauroursodeoxycholic acid; VPA, valproic acid

cellular determinant of recombinant protein productivity in Chinese hamster ovary (CHO) cells.^[27–29] Nocodazole treated cells were found to be up to 27% larger than control cells. Nevertheless, this phenotypic variation was not observed with M344, in which the increase in titre was not accompanied by an increase in cell volume. It may therefore be inferred that these molecules modulate rAAV expression via distinct mechanisms independent of each other and that increased control of rAAV production may be achieved by the application of specific combinations of small molecule effectors.


3.2 | Early addition of nocodazole enhances rAAV8 production in HEK293 cells

A recent study showed that *cap* gene expression, translation and assembly of Cap proteins into empty AAV particles is a kinetically rapid process.^[30] Approximately 80% of capsids are assembled within the first 24 HPT whereas Rep mediated replication of rAAV genome from

the *cis*-ITR plasmid is slower, peaking after capsid protein levels have plateaued due to the inhibitory action of Rep binding to the packaging plasmid and inhibiting transcription or by translational repression of *cap* mRNA. As capsid secretion from the nucleus into the cytoplasm is independent of genome loading, pre-assembled empty capsids can be secreted from the site of rAAV genome loading, thus depleting the pool of empty capsids available to newly replicated rAAV genome.^[32,31] Therefore, we hypothesised that the effect of a given chemical effector may be positive (or further enhanced), neutral or negative with respect to the timing of its deployment.

To further investigate the impact of nocodazole in enhancing rAAV production, we deployed high dose nocodazole (4 μ M) between 0 and 48 HPT (Figure 2). Addition of 4 μ M nocodazole immediately (0 HPT) and 4 HPT resulted in a considerable reduction in VCD at 72 HPT of 74% and 64% respectively, compared to rAAV8 producing cells without nocodazole (Ctrl) (Figure 2A). Also apparent at early addition time-points was a slight reduction in cell viability ($p > 0.05$; Figure 2B) and a significantly higher mean cell volume compared to cultures not treated

FIGURE 2 Addition of nocodazole to rAAV8 producing cells to increase genome titre is time-dependent. rAAV8 producing cells were cultured in 24-well microplates and 4 μ M nocodazole was added at 0-, 4-, 24-, or 48-HPT or left untreated (Ctrl). At 72 HPT cells were harvested and VCD (A), viability (B) and mean cell volume (C) was measured. Final crude genome titre expressed as a fold change relative to Ctrl is shown in (D). Data shown for VCD, viability and mean cell diameter are the mean \pm SEM. $n > 3$ independent biological replicates. Data shown for genome titre fold change are the mean \pm SEM. $n \geq 3$ independent biological replicates. Data were analysed by one-way ANOVA followed by post-hoc Holm-Šidák multiple comparisons test with respect to Ctrl. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. ANOVA, analysis of variance; HPT, hours post-transfection; SEM, standard error of mean; VCD, viable cell density



with nocodazole (up to 23%; Figure 2C), consistent with previous work by Tait et al. (2004) who observed increased cell size and decreased viability in nocodazole treated CHO cells producing a recombinant monoclonal antibody. Most strikingly, addition of nocodazole at 4 HPT resulted in a 2.2-fold increase in rAAV8 genome titre at harvest compared to control cells (Figure 2D). Addition at the earlier timepoint of 0 HPT was sub-optimal, with a 10% reduction in rAAV8 titre compared to the titre of cells treated at 4 HPT (Figure 2D). We therefore conclude that early addition (\sim 4 HPT) of nocodazole to rAAV producing cells is an effective positive mediator of rAAV production in a small-scale, transient expression and suspension HEK cell system.

3.3 | Nocodazole improves rAAV genome titre in two different serotypes

To investigate the effect of nocodazole addition in a system more representative of large scale rAAV production, culture volume was scaled up from the initial microplate culture volume of 0.7–30 ml culture volume in shake flasks. To rule out a serotype-dependent effect of nocodazole addition, plasmids for both rAAV8 and rAAV9 serotypes were separately transfected in HEK293 cells and cultured with and without the addition of 4 μ M nocodazole. rAAV genome titre was measured from 24 to 72 HPT. All measured parameters of nocoda-

zole induced cell cycle arrest (reduced VCD, decreased viability and increased mean cell volume) and increased rAAV genome titre were consistent with those seen at smaller culture volumes (Figure 3A,B). Comparable to microplate-based cultures, mean viral genome titre was increased by up to 2.5-fold in nocodazole-treated cultures compared to untreated cultures (Figure 3C). Importantly there were no observed significant differences in the above-described measurements between cultures producing rAAV8 or rAAV9, suggesting a broad applicability for nocodazole addition in rAAV manufacturing.

3.4 | rAAV producing cultures treated with nocodazole have an increased proportion of cells in G2/M phase

Nocodazole is an anti-mitotic agent, used as both a chemotherapeutic and as a common agent of cell cycle synchronisation.^[17,32–34] Nocodazole exerts its effect by reversibly inhibiting the polymerisation of β -tubulin, destabilising microtubules and preventing the formation of mitotic spindles, thus arresting cells within the G2/M phase of the cell cycle. Cells treated with nocodazole typically enter mitosis but are unable to progress through cytokinesis, leading to either apoptosis in cells remaining in arrested mitosis for an extended period of time, or subsequent “mitotic slippage” into G0/G1 phase followed




FIGURE 3 Increased genome titre in nocodazole treated cells is maintained in larger scale cultures and across two separate serotypes. 30 ml shake flask cultures were transfected with rAAV8 or rAAV9 producing plasmids and cultured for 72 HPT in the presence (rAAV8: ○; rAAV9: □) or absence (rAAV8: ●; rAAV9: ■) of 4 μM nocodazole added 4 HPT. Cultures were measured daily for VCD (A – solid lines), viability (A – dashed lines) and mean cell volume (B). Fold change analysis of genome titre for both serotypes in the presence (+) or absence (–) of 4 μM nocodazole at 72 HPT is shown in (C). Data shown are the mean ± SEM. $n = 3$ independent biological replicates. Fold change between nocodazole treated and untreated cultures was analysed for each serotype separately by Student's unpaired two-tailed t -test with respect to untreated cultures. ** $p < 0.01$, *** $p < 0.001$. HPT, hours post-transfection; rAAV, recombinant adeno-associated virus; SEM, standard error of mean; VCD, viable cell density

by apoptosis.^[34–37] In addition to its use as a cell synchronisation agent, nocodazole has previously been shown to increase transient recombinant protein expression in a mammalian cell system.^[38]

Flow cytometry was carried out to determine the cell cycle status of rAAV8-producing cultures treated with nocodazole. Untreated rAAV8 producing cells were found to be almost entirely in either G1 or S phase at 72 HPT (Figure 4A). Cells treated with 4 μM nocodazole at the point of transfection (0 HPT) resulted in a very significant proportion (38%) arresting in G2/M phase (Figure 3B). The ratio of cells in G2/M:G1 phase was found to decrease the later nocodazole was added (Figure 4C). Of note is the observation that a significant number (26%) of cells remain arrested in G2/M phase at 72 HPT when nocodazole is added as late as 24 HPT, yet the positive effect on rAAV8 genome titre is substantially lessened compared to earlier treatment. This would suggest a critical temporal component to the addition of nocodazole, such that later additions to cell culture are sub-optimal in terms of producing high rAAV titres, likely due to the rapid assembly process of capsid proteins that largely occurred within 24 HPT.^[30]

The nucleolus is a dynamic compartment within the nucleus which undergoes extensive remodelling during cell cycle progression, particularly during mitosis.^[39] Previous immunocytochemical examination of nucleolar localisation throughout normal cell cycle progression shows a distinctive dispersal of nucleolar protein staining throughout the cytoplasm during prometaphase and metaphase – concomitant with the breakdown of the nuclear membrane during mitosis.^[40–42] Nucle-

olar proteins in cells in interphase and prophase are typically found located within the nucleus itself. Of note, the nucleolus is considered to be a likely site for AAV capsid assembly and Rep-mediated loading of AAV genome into capsids,^[43–46] as well as being linked more generally to viral replication in other human viruses.^[47]

Cells from rAAV8 producing cultures – both with and without nocodazole addition 4 HPT – were harvested and fixed at 24 HPT. Cells were stained with a nucleolar marker (fibrillarin – a protein component of the nucleolus associated with ribosomal RNA processing^[41]) and DAPI (a nuclear DNA stain). Widefield fluorescent microscopy was used to visualise the phenotypic changes induced by nocodazole addition. Untreated cells displayed highly localised or punctate staining of fibrillarin within the area of nuclear DNA staining (Figure 4D), indicative of cells in interphase or prophase. In contrast, cells treated with nocodazole exhibited a proportion displaying a disorganised nuclear phenotype – with fibrillarin distributed broadly throughout the cytoplasm, and with condensed nuclear DNA (Figure 4E) – indicative of cells either progressing through mitosis or arrested within G2/M phase.

3.5 | Small molecule additives can be combined to further enhance rAAV8 production

In order to evaluate whether specific combinations of effectors could act synergistically to further increase rAAV production, we utilised




FIGURE 4 rAAV8 producing cells treated with nocodazole arrest in G2/M phase. Flow cytometry histograms triggered against propidium iodide signal for cells show the relative abundance of cells in either G1 (blue), S (orange) or G2/M (green) phases of the cell cycle in the absence (A) or presence (B) of 4 μM nocodazole addition at 0 HPT. Ratio of cells in G2/M phase to G1 phase at 72 HPT with 4 μM nocodazole added at 0, 4, 24 and 48 HPT or untreated (Ctrl) (C). Representative fluorescent composite images of rAAV-producing cells fixed 24 HPT show staining of the fibrillar component of the nucleolus with anti-fibrillarin (red) and nuclear DNA with DAPI (blue). Cells displaying disorganised nucleolar morphology are indicated by white arrows in non-treated cells (D) and cells treated 4 HPT with 4 μM nocodazole (E). Images taken using 100 \times oil objective. Scale bar 10 μm . Data shown in (C) are mean \pm SEM for three biological replicates. HPT, hours post-transfection; rAAV, recombinant adeno-associated virus; SEM, standard error of mean

nocodazole in combination with either z-VAD-fmk or M344 (see Figure 1). M344 is a synthetic analogue of the anti-fungal drug Trichostatin A, an inhibitor of Class I and IIB histone deacetylases and recently used as an enhancer of recombinant protein expression in mammalian cell culture.^[10] Z-VAD-fmk is a pan-caspase inhibitor.^[19] Each chemical was added to rAAV8 producing HEK293 cultures together with nocodazole at 4 HPT in 24-well microplates. The inclusion of z-VAD-fmk in the initial screening experiment was predicated on its anti-caspase activity, as we hypothesised caspase mediated apoptosis – linked to rAAV production and expression of AAV2 Rep proteins – would negatively affect final crude titre.^[50,49] Additionally, caspase-mediated apoptosis induced by nocodazole-mediated cell cycle dysregulation would further increase cell death within the production cultures. Increased cell viability and VCD in cultures treated with nocodazole/z-VAD-fmk relative to untreated, nocodazole treated or nocodazole/M344 treated cells suggest that apoptosis was reduced (Figure 5A,B) but with an unexpected reduction in crude genome titre (Figure 5D). The observed reduction may be a consequence of

off-target induction of autophagy via inactivation of *n*-glycanase 1 (NGLY1) that has been shown to occur in HEK293 cells treated with z-VAD-fmk.^[50] While the role of autophagy in rAAV production is undetermined, inhibition of autophagy has been shown to increase recombinant protein expression in CHO cells^[51,52] and unintentional upregulation of autophagy may result in a reduction in viral component proteins necessary for production of high viral titres. Interestingly, the highest mean cell volume, which appeared to correlate positively with genome titre, was measured in cells treated with both nocodazole and z-VAD-fmk (Figure 5C). This may be a result of reduced apoptotic cell death allowing cell size to increase but with the caveat that any benefit gained from this from a production perspective is attenuated by the potential negative off-target effects of z-VAD-fmk.

We observed that the combination of 2.5 μM M344 and 4 μM nocodazole produced an additive effect, increasing crude rAAV genome titre 2.6-fold compared to untreated cultures, an improvement on nocodazole alone (two-fold increase compared to untreated) (Figure 5D). This additive effect was also observed in 30 ml shake




FIGURE 5 Combinatorial use of small molecule enhancers has an additive effect on genome titre. rAAV8 producing cells were treated 4 HPT with small molecule enhancers of genome titre or left untreated. Cells were harvested 72 HPT and measurements taken of VCD (A), viability (B), mean cell volume (C) and rAAV8 genome titre as a fold change with respect to untreated cells (–/–/–) (D). Data shown are the mean \pm SEM. $n = 3$ independent biological replicates. Data were analysed by one-way ANOVA followed by post-hoc Holm-Šidák multiple comparisons test with respect to untreated cells (–/–/–). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. ANOVA, analysis of variance; HPT, hours post-transfection; SEM, standard error of mean; VCD, viable cell density




FIGURE 6 Genome titre improvements are retained in larger scale cultures. 30 ml shake flask cultures were transfected with rAAV8 producing plasmids with no chemical additives (■), with the addition of 4 μM nocodazole at 4 HPT (○) or with the addition of 4 μM nocodazole and 2.5 μM M344 at 4 HPT (□). Cultures were measured daily for VCD (A – solid lines) and viability (A – dashed lines). Genome titre was measured 72 HPT and is shown as fold change with respect to untreated cultures (B). Data shown are the mean \pm SEM. $n = 3$ independent biological replicates. Data were analysed by one-way ANOVA followed by post-hoc Holm-Šidák multiple comparisons test with respect to untreated cells (–/–). * $p < 0.05$, ** $p < 0.01$. ANOVA, analysis of variance; HPT, hours post-transfection; SEM, standard error of mean; VCD, viable cell density

flask cultures, whereby measurements of VCD and viability closely replicated those observed in the screening assay (Figure 6A), together with an improvement in genome titre with nocodazole/M344 from a 2.6-fold increase in the screening assay to a three-fold increase com-

pared to untreated cells in larger volume cultures (Figure 6B). AAV8 intact capsid-specific ELISA analysis of total capsid titre showed a significant increase in intact capsids after addition of nocodazole (4.3-fold increase) and nocodazole/M344 (11.3-fold increase) compared to

untreated controls (data not shown). While this increase in the relative ratio of empty to full capsids is suboptimal in terms of commonly assessed product quality attributes, recent improvements in downstream processing of crude AAV lysate will likely reduce the impacts of excess empty capsids during final product formulation, whilst retaining the benefits of increased genome titre.^[53] Additionally, we anticipate that rAAV vector development could complement the process engineering strategy to further maximise rAAV titre (e.g., high intact capsid levels are likely to benefit from hybrid Rep with improved genome packaging efficiency)^[54] while combinatorial empirical modelling will enable systematic determination of optimal chemical dosage and timing.

Taken together, these data show that nocodazole, either alone or in combination with select small molecules, can reproducibly boost both genome and total viral particle titre in a transient suspension HEK293 rAAV production system and that it is both scalable and applicable to production of rAAVs derived from two phylogenetically distinct and clinically translatable pseudotyped capsids.

4 | DISCUSSION

Improving the yield of intact, genome-containing rAAV particles during viral vector production is a critical step to reducing overall production costs. Here, we describe a simple and robust method by which viral vector genome titre, a fundamental quality attribute of viral vector production, may be quickly improved in an established and previously optimised suspension culture system. Small molecule enhancers of recombinant protein expression have been extensively used across a wide range of mammalian cell systems to improve transient production performance.^[8,55–56,21,38,57,58] The ease of use and low cost of small molecule enhancers (particularly for chemicals with pronounced biological activity at low dosages) makes them an attractive solution to improving rAAV yield.

Investigation of the cellular mechanisms underpinning increased viral genome titre point to the arrest of rAAV producing cells in mitosis soon after PEI-mediated transient transfection of rAAV producing plasmids. Prior studies have shown a strong preference for wildtype AAV replication within the G2/M phase of the cell cycle.^[59,60] Nocodazole has been shown to significantly improve transient transfection efficiency in CHO cells,^[38] which may stem from increased nuclear permissibility of transfection complexes due to the breakdown of the nuclear membrane during mitosis. A reduction in cell proliferation caused by nocodazole addition may also benefit viral production by reducing plasmid copy number dilution and maintaining mRNA transcript levels.^[56] A recent study utilising a CRISPR-mediated genome wide screening strategy identified two target genes (ITPRIP and SKA2) that when modulated in cells increased rAAV genome titre and improved full/empty capsid ratios, with both target genes (strongly, in the case of SKA2) associated with cell cycle modulation.^[61] Further to this, a proteomic study of HEK cells during AAV5 production highlighted a number of proteins involved in cell cycle and proliferation as being strongly downregulated during

production.^[62] The molecular effects of cell cycle arrest within the G2/M phase on rAAV production are unknown, but there is a potential correlation between the loss of essential nucleolar functions and the nucleolar localisation of viral proteins, while the volume increase could possibly minimise crowding effects due to accumulation of viral proteins.^[63] This apparent link between the cell cycle and AAV production, and the abundance of cell cycle modulating molecules, necessitates further investigation into the use of cell cycle modulators for both improving rAAV production yields and ultimately improving our understanding of the underlying biological processes governing rAAV production.

The apparent important temporal aspect of cell cycle regulation within the production process may also provide avenues for non-chemical interventions to improve vector yield as this relationship becomes better understood. Whilst we have not investigated the mechanism behind M344-mediated titre enhancement, HDAC6 (of which M344 is a selective inhibitor) has been shown to bind to, and regulate clearance of, ubiquitinated proteins via induction of the heat-shock cellular response.^[64] AAV capsid proteins are a known target of ubiquitination post-viral entry,^[65] and the ubiquitin-proteasome pathway (UPP) has been suggested to play an active role in AAV capsid monomer degradation,^[66] therefore we posit a link between M344-mediated UPP dysregulation and increased crude viral titre. Due to the robustness of the results between small-scale plate-based cultures and larger scale shake flasks, we believe that the screening process shown here could be further scaled down and automated to increase throughput, due to the availability of instrumentation that can rapidly and accurately dispense very small volumes of drugs into culture. As minimal volumes are required for ddPCR analysis of genome titre, identification of novel enhancers of rAAV could be rapidly incorporated into existing rAAV production platforms with minimal changes to existing protocols.

In summary, we show that the use of readily available small molecule enhancers can significantly improve rAAV production yield. We show that small molecule enhancers of rAAV production are amenable to optimisation in an existing suspension HEK293 cell system and that positive hits from initial small-scale screening of enhancer molecules are translatable to improvements in genome titre up to at least 30 ml shake flask scale, with the potential for translation to commercially viable volumetric production (>10 L), as has been demonstrated for a similar production system.^[67] We also show that increased titre resulting from nocodazole treatment is consistent across two different serotypes, suggesting broad applicability in rAAV manufacturing.

AUTHOR CONTRIBUTIONS

Joseph M. Scarrott: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Writing – original draft. Yusuf B. Johari: Formal analysis; Investigation; Methodology; Writing – review & editing. Thilo H. Pohle: Formal analysis; Investigation; Methodology; Writing – review & editing. Ping Liu: Conceptualization; Project administration; Resources; Supervision; Writing – review & editing. Ayda Mayer: Conceptualization; Project administration; Resources; Supervision; Writing – review & editing. David C. James: Conceptualization;

Funding acquisition; Methodology; Project administration; Resources; Supervision; Writing – review & editing.

ACKNOWLEDGEMENTS

This study was supported by REGENXBIO Inc., U.S.A. The authors thank Susan Clark (University of Sheffield) for technical assistance in flow cytometry analysis and Lynne Baxter (University of Sheffield) for access to widefield fluorescence microscopy equipment.

CONFLICTS OF INTEREST

Part of this work was conducted under a research agreement between the University of Sheffield and REGENXBIO Inc. Ping Liu and Ayda Mayer are employed by REGENXBIO Inc. and hold shares in the company.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the lead author upon request. Please contact j.scarrott@sheffield.ac.uk for data.

ORCID

Joseph M. Scarrott  <https://orcid.org/0000-0002-6046-7687>

Yusuf B. Johari  <https://orcid.org/0000-0001-9933-5764>

REFERENCES

- Bulaklak, K., & Gersbach, C. A. (2020). The once and future gene therapy. *Nature Communications*, 11, 11–14.
- Kuzmin, D. A., Shutova, M. V., Johnston, N. R., Smith, O. P., Fedorin, V. V., Kukushkin, Y. S., van der Loo, J. C. M., & Johnstone, E. C. (2021). The clinical landscape for AAV gene therapies. *Nature Reviews Drug Discovery*, 20, 173–174.
- Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L'Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., ... Kaspar, B. K. (2017). Single-dose gene-replacement therapy for spinal muscular atrophy. *New England Journal of Medicine*, 377, 1713–1722.
- Xiao, X., Li, J., & Samulski, R. J. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. *Journal of Virology*, 72, 2224–2232.
- Maurer, A. C., & Weitzman, M. D. (2020). Adeno-associated virus genome interactions important for vector production and transduction. *Human Gene Therapy*, 31, 499–511.
- Meier, A. F., Fraefel, C., & Seyffert, M. (2020). The interplay between adeno-associated virus and its helper viruses. *Viruses*, 12, 8–12.
- Sha, S., Maloney, A. J., Katsikis, G., Nguyen, T. N. T., Neufeld, C., Wolfrum, J., Barone, P. W., Springs, S. L., Manalis, S. R., Sinskey, A. J., & Braatz, R. D. (2021). Cellular pathways of recombinant adeno-associated virus production for gene therapy. *Biotechnology Advances*, 49, 107764.
- Chang, J., Chen, X., Wang, R., Shi, R., Wang, X., Lu, W., Ma, S., & Xia, Q. (2020). High-throughput screening identifies two novel small molecule enhancers of recombinant protein expression. *Molecules (Basel, Switzerland)*, 25, 353.
- Zhao, H., Lee, K. J., Daris, M., Lin, Y., Wolfe, T., Sheng, J., Plewa, C., Wang, S., & Meisen, W. H. (2020). Creation of a high-yield AAV vector production platform in suspension cells using a design-of-experiment approach. *Molecular Therapy – Methods & Clinical Development*, 18, 312–320.
- Yu, C., Trivedi, P. D., Chaudhuri, P., Bhake, R., Johnson, E. J., Caton, T., Potter, M., Byrne, B. J., & Clément, N. (2021). NaCl and KCl mediate log increase in AAV vector particles and infectious titers in a specific/timely manner with the HSV platform. *Molecular Therapy – Methods & Clinical Development*, 21, 1–13.
- Hildinger, M., Baldi, L., Stettler, M., & Wurm, F. M. (2007). High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells. *Biotechnology Letters*, 29, 1713–1721.
- Duetz, W. A., Rüedi, L., Hermann, R., O'Connor, K., Büchs, J., & Witholt, B. (2000). Methods for intense aeration, growth, storage, and replication of bacterial strains in microtiter plates. *Applied and Environmental Microbiology*, 66, 2641–2646.
- Wang, Q., Nambiar, K., & Wilson, J. M. (2021). Isolating natural adeno-associated viruses from primate tissues with a high-fidelity polymerase. *Human Gene Therapy*, 32, 1439–1449.
- Kusaczuk, M. (2019). Tauroursodeoxycholate—bile acid with chaperone activity: Molecular and cellular effects and therapeutic perspectives. *Cells*, 8, 1471.
- Zou, Q., Bennion, B. J., Daggett, V., & Murphy, K. P. (2002). The molecular mechanism of stabilization of proteins by TMAO and its ability to counteract the effects of urea. *Journal of the American Chemical Society*, 124, 1192–1202.
- Roth, S. D., Schütttrumpf, J., Milanov, P., Abriss, D., Ungerer, C., Quade-Lyssa, P., Simpson, J. C., Pepperkok, R., Seifried, E., & Tonn, T. (2012). Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A. *PLoS ONE*, 7, e44505.
- Blajeski, A. L., Phan, V. A., Kottke, T. J., & Kaufmann, S. H. (2002). G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells. *Journal of Clinical Investigation*, 110, 91–99.
- Steehmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., Grauert, M., Adolf, G. R., Kraut, N., Peters, J. M., & Rettig, W. J. (2007). BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. *Current Biology*, 17, 316–322.
- Li, X., Yao, X., Zhu, Y., Zhang, H., Wang, H., Ma, Q., Yan, F., Yang, Y., Zhang, J., Shi, H., Ning, Z., Dai, J., Li, Z., Li, C., Su, F., Xue, Y., Meng, X., Dong, G., & Xiong, H. (2019). The caspase inhibitor Z-VAD-FMK alleviates endotoxic shock via inducing macrophages necroptosis and promoting MDSCs-mediated inhibition of macrophages activation. *Frontiers in Immunology*, 10, 1824.
- Mimura, Y., Lund, J., Church, S., Dong, S., Li, J., Goodall, M., & Jefferis, R. (2001). Butyrate increases production of human chimeric IgG in CHO-K1 cells whilst maintaining function and glycoform profile. *Journal of Immunological Methods*, 247, 205–216.
- Yang, W. C., Lu, J., Nguyen, N. B., Zhang, A., Healy, N. V., Kshirsagar, R., Ryll, T., & Huang, Y. M. (2014). Addition of valproic acid to CHO cell fed-batch cultures improves monoclonal antibody titers. *Molecular Biotechnology*, 56, 421–428.
- Riessland, M., Brichta, L., Hahnen, E., & Wirth, B. (2006). The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. *Human Genetics*, 120, 101–110.
- Wong, V. V. T., Ho, K. W., & Yap, M. G. S. (2004). Evaluation of insulin-mimetic trace metals as insulin replacements in mammalian cell cultures. *Cytotechnology*, 45, 107–115.
- Mitchell, A. M., & Samulski, R. J. (2013). Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors. *Journal of Virology*, 87, 13035–13041.
- Jennings, K., Miyamae, T., Traister, R., Marinov, A., Katakura, S., Sowders, D., Trapnell, B., Wilson, J. M., Gao, G., & Hirsch, R. (2005). Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo. *Molecular Therapy*, 11, 600–607.

26. Wu, M., Chen, P., Liu, F., Lv, B., Ge, M., Jiang, P., Xu, W., Liu, X., & Yang, D. (2021). ONX0912, a selective oral proteasome inhibitor, triggering mitochondrial apoptosis and mitophagy in liver cancer. *Biochemical and Biophysical Research Communications*, 547, 102–110.
27. Fernandez-Martell, A., Johari, Y. B., & James, D. C. (2018). Metabolic phenotyping of CHO cells varying in cellular biomass accumulation and maintenance during fed-batch culture. *Biotechnology and Bioengineering*, 115, 645–660.
28. Lloyd, D. R., Holmes, P., Jackson, L. P., Emery, A. N., & Al-Rubeai, M. (2000). Relationship between cell size, cell cycle and specific recombinant protein productivity. *Cytotechnology*, 34, 59–70.
29. Pan, X., Dalm, C., Wijffels, R. H., & Martens, D. E. (2017). Metabolic characterization of a CHO cell size increase phase in fed-batch cultures. *Applied Microbiology and Biotechnology*, 101, 8101–8113.
30. Nguyen, T. N. T., Sha, S., Hong, M. S., Maloney, A. J., Barone, P. W., Neufeld, C., Wolfrum, J., Springs, S. L., Sinskey, A. J., & Braatz, R. D. (2021). Mechanistic model for production of recombinant adeno-associated virus via triple transfection of HEK293 cells. *Molecular Therapy—Methods & Clinical Development*, 21, 642–655.
31. Trempe, J. P., & Carter, B. J. (1988). Regulation of adeno-associated virus gene expression in 293 cells: Control of mRNA abundance and translation. *Journal of Virology*, 62, 68–74.
32. Beswick, R. W., Ambrose, H. E., & Wagner, S. D. (2006). Nocodazole, a microtubule depolymerising agent, induces apoptosis of chronic lymphocytic leukaemia cells associated with changes in Bcl-2 phosphorylation and expression. *Leukemia Research*, 30, 427–436.
33. Bernard, D., Mondesert, O., Gomes, A., Duthen, Y., & Lobjois, V. (2019). A checkpoint-oriented cell cycle simulation model. *Cell Cycle*, 18, 795–808.
34. Uetake, Y., & Sluder, G. (2007). Cell-cycle progression without an intact microtubule cytoskeleton. *Current Biology*, 17, 2081–2086.
35. Vasquez, R. J., Howell, B., Yvon, A. M. C., Wadsworth, P., & Cassimeris, L. (1997). Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro. *Molecular Biology of the Cell*, 8, 973–985.
36. Rieder, C. L., & Maiato, H. (2004). Stuck in division or passing through. *Developmental Cell*, 7, 637–651.
37. Quignon, F., Rozier, L., Lachages, A. M., Bieth, A., Simili, M., & Debatisse, M. (2007). Sustained mitotic block elicits DNA breaks: One-step alteration of ploidy and chromosome integrity in mammalian cells. *Oncogene*, 26, 165–172.
38. Tait, A. S., Brown, C. J., Galbraith, D. J., Hines, M. J., Hoare, M., Birch, J. R., & James, D. C. (2004). Transient production of recombinant proteins by Chinese hamster ovary cells using polyethyleneimine/DNA complexes in combination with microtubule disrupting anti-mitotic agents. *Biotechnology and Bioengineering*, 88, 707–721.
39. Hernandez-Verdun, D. (2011). Assembly and disassembly of the nucleolus during the cell cycle. *Nucleus*, 2, 189–194.
40. Ma, N., Matsunaga, S., Takata, H., Ono-Maniwa, R., Uchiyama, S., & Fukui, K. (2007). Nucleolin functions in nucleolus formation and chromosome congression. *Journal of Cell Science*, 120, 2091–2105.
41. Amin, M. A., Matsunaga, S., Ma, N., Takata, H., Yokoyama, M., Uchiyama, S., & Fukui, K. (2007). Fibrillarin, a nucleolar protein, is required for normal nuclear morphology and cellular growth in HeLa cells. *Biochemical and Biophysical Research Communications*, 360, 320–326.
42. Stenström, L., Mahdessian, D., Gnann, C., Cesnik, A. J., Ouyang, W., Leonetti, M. D., Uhlén, M., Cuylen-Haering, S., Thul, P. J., & Lundberg, E. (2020). Mapping the nucleolar proteome reveals a spatiotemporal organization related to intrinsic protein disorder. *Molecular Systems Biology*, 16, 1–16.
43. Wistuba, A., Kern, A., Weger, S., Grimm, D., & Kleinschmidt, J. A. (1997). Subcellular compartmentalization of adeno-associated virus type 2 assembly. *Journal of Virology*, 71, 1341–1352.
44. Sonntag, F., Schmidt, K., & Kleinschmidt, J. A. (2010). A viral assembly factor promotes AAV2 capsid formation in the nucleolus. *Proceedings of the National Academy of Sciences of the United States of America*, 107, 10220–10225.
45. Qiu, J., & Brown, K. E. (1999). A 110-kDa nuclear shuttle protein, nucleolin, specifically binds to adeno-associated virus type 2 (AAV-2) capsid. *Virology*, 257, 373–382.
46. Bevington, J. M., Needham, P. G., Verrill, K. C., Collaco, R. F., Basrur, V., & Trempe, J. P. (2007). Adeno-associated virus interactions with B23/Nucleophosmin: Identification of sub-nucleolar virion regions. *Virology*, 357, 102–113.
47. Greco, A. (2009). Involvement of the nucleolus in replication of human viruses. *Reviews in Medical Virology*, 19, 201–214.
48. Saudan, P., Vlach, J., & Beard, P. (2000). Inhibition of S-phase progression by adeno-associated virus Rep78 protein is mediated by hypophosphorylated pRb. *The EMBO Journal*, 19, 4351–4361.
49. Berthet, C., Raj, K., Saudan, P., & Beard, P. (2005). How adeno-associated virus Rep78 protein arrests cells completely in S phase. *Proceedings of the National Academy of Sciences of the United States of America*, 102, 13634–13639.
50. Needs, S. H., Bootman, M. D., Grotzke, J. E., Kramer, H. B., & Allman, S. A. (2022). Off-target inhibition of NGLY1 by the polycaspase inhibitor Z-VAD-fmk induces cellular autophagy. *The FEBS Journal*, 1–17. <https://doi.org/10.1111/febs.16345>
51. Jardon, M. A., Sattha, B., Braasch, K., Leung, A. O., Côté, H. C. F., Butler, M., Gorski, S. M., & Piret, J. M. (2012). Inhibition of glutamine-dependent autophagy increases t-PA production in CHO Cell fed-batch processes. *Biotechnology and Bioengineering*, 109, 1228–1238.
52. Nasser, S. S., Ghaffari, N., Braasch, K., Jardon, M. A., Butler, M., Kennard, M., Gopaluni, B., & Piret, J. M. (2014). Increased CHO cell fed-batch monoclonal antibody production using the autophagy inhibitor 3-MA or gradually increasing osmolality. *Biochemical Engineering Journal*, 91, 37–45.
53. Dickerson, R., Argento, C., Pieracci, J., & Bakhshayeshi, M. (2020). Separating empty and full recombinant adeno-associated virus particles using isocratic anion exchange chromatography. *Biotechnology Journal*, 2000015, 1–9.
54. Mietsch, M., Eddington, C., Jose, A., Hsi, J., Chipman, P., Henley, T., Choudhry, M., McKenna, R., & Agbandje-McKenna, M. (2021). Improved genome packaging efficiency of adeno-associated virus vectors using rep hybrids. *Journal of Virology*, 95, 1–19.
55. Johari, Y. B., Estes, S. D., Alves, C. S., Sinacore, M. S., & James, D. C. (2015). Integrated cell and process engineering for improved transient production of a 'difficult-to-express' fusion protein by CHO cells. *Biotechnology and Bioengineering*, 112, 2527–2542.
56. Meyer, H. J., Turincio, R., Ng, S., Li, J., Wilson, B., Chan, P., Zak, M., Reilly, D., Beresini, M. H., & Wong, A. W. (2017). High throughput screening identifies novel, cell cycle-arresting small molecule enhancers of transient protein expression. *Biotechnology Progress*, 33, 1579–1588.
57. Allen, M. J., Boyce, J. P., Trentalange, M. T., Treiber, D. L., Rasmussen, B., Tillotson, B., Davis, R., & Reddy, P. (2008). Identification of novel small molecule enhancers of protein production by cultured mammalian cells. *Biotechnology and Bioengineering*, 100, 1193–1204.
58. Johari, Y. B., Jaffé, S. R. P., Scarrott, J. M., Johnson, A. O., Mozzanino, T., Pohle, T. H., Maisuria, S., Bhayat-Cammack, A., Lambiase, G., Brown, A. J., Tee, K. L., Jackson, P. J., Wong, T. S., Dickman, M. J., Sargur, R. B., & James, D. C. (2021). Production of trimeric SARS-CoV-2 spike protein by CHO cells for serological COVID-19 testing. *Biotechnology and Bioengineering*, 118, 1013–1021.
59. Franzoso, F. D., Seyffert, M., Vogel, R., Yakimovich, A., de Andrade Pereira, B., Meier, A. F., Sutter, S. O., Tobler, K., Vogt, B., Greber, U. F., Büning, H., Ackermann, M., & Fraefel, C. (2017). Cell cycle-dependent expression of adeno-associated virus 2 (AAV2) rep in coinfections with herpes simplex virus 1 (HSV-1) gives rise to a mosaic of cells replicating either AAV2 or HSV-1. *Journal of Virology*, 91, 1–19.
60. Raj, K., Ogston, P., & Beard, P. (2001). Virus-mediated killing of cells that lack p53 activity. *Nature*, 412, 914–917.

61. Barnes, C. R., Lee, H., Ojala, D. S., Lewis, K. K., Limsirichai, P., & Schaffer, D. V. (2021). Genome-wide activation screens to increase adeno-associated virus production. *Molecular Therapy Nucleic Acids*, *26*, 94–103.
62. Strasser, L., Boi, S., Guapo, F., Donohue, N., Barron, N., Rainbow-fletcher, A., & Bones, J. (2021). Proteomic landscape of adeno-associated virus (AAV)-producing HEK293 cells. *International Journal of Molecular Sciences*, *22*, 11499.
63. Matthews, D., Emmott, E., & Hiscox, J. (2011). Viruses and the nucleus. *Protein Reviews*, *15*, 321–345.
64. Boyault, C., Zhang, Y., Fritah, S., Caron, C., Gilquin, B., So, H. K., Garrido, C., Yao, T. P., Vourc'h, C., Matthias, P., & Khochbin, S. (2007). HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. *Genes & Development*, *21*, 2172–2181.
65. Yan, Z., Zak, R., Luxton, G. W. G., Ritchie, T. C., Bantel-Schaal, U., & Engelhardt, J. F. (2002). Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. *Journal of Virology*, *76*, 2043–2053.
66. Maurer, A. C., Pacouret, S., Cepeda Diaz, A. K., Blake, J., Andres-Mateos, E., & Vandenberghe, L. H. (2018). The assembly-activating protein promotes stability and interactions between AAV's viral proteins to nucleate capsid assembly. *Cell Reports*, *23*, 1817–1830.
67. Grieger, J. C., Soltys, S. M., & Samulski, R. J. (2016). Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. *Molecular Therapy*, *24*, 287–297.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Scarrott, J. M., Johari, Y. B., Pohle, T. H., Liu, P., Mayer, A., & James, D. C. (2022). Increased recombinant adeno-associated virus production by HEK293 cells using small molecule chemical additives. *Biotechnology Journal*, e2200450. <https://doi.org/10.1002/biot.202200450>